Scarica l'app Stockscreener
11.90
1.19%
0.14
Dopo l'orario di chiusura:
11.84
-0.06
-0.50%
Precedente Chiudi:
$11.76
Aprire:
$11.96
Volume 24 ore:
1.58M
Relative Volume:
0.94
Capitalizzazione di mercato:
$1.33B
Reddito:
-
Utile/perdita netta:
$-129.47M
Rapporto P/E:
-7.8569
EPS:
-1.5146
Flusso di cassa netto:
$-114.08M
1 W Prestazione:
-13.20%
1M Prestazione:
+19.12%
6M Prestazione:
+10.39%
1 anno Prestazione:
+54.55%
Intervallo 1D:
$11.46
$12.17
Intervallo di 1 settimana:
$10.98
$12.95
Portata 52W:
$3.8951
$14.93
Oric Pharmaceuticals Inc Stock (ORIC) Company Profile
Nome
Oric Pharmaceuticals Inc
Settore
Industria
Telefono
(650) 388-5600
Indirizzo
240 E. GRAND AVE., SOUTH SAN FRANCISCO, CA
Compare ORIC vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ORIC
Oric Pharmaceuticals Inc
|
11.90 | 1.33B | 0 | -129.47M | -114.08M | -1.5146 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.34 | 119.23B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
745.77 | 78.84B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
700.45 | 43.35B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
313.41 | 41.57B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.05 | 31.51B | 5.36B | 287.73M | 924.18M | 2.5229 |
Oric Pharmaceuticals Inc Stock (ORIC) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-07 | Iniziato | Piper Sandler | Overweight |
| 2025-11-20 | Iniziato | Evercore ISI | Outperform |
| 2025-11-18 | Iniziato | Wolfe Research | Peer Perform |
| 2025-09-04 | Ripresa | Guggenheim | Buy |
| 2025-07-08 | Iniziato | Ladenburg Thalmann | Buy |
| 2024-10-31 | Iniziato | Wells Fargo | Overweight |
| 2024-09-06 | Iniziato | Stifel | Buy |
| 2024-02-23 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-09-22 | Iniziato | Wedbush | Outperform |
| 2023-03-23 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2023-03-21 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2023-03-16 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2022-07-18 | Ripresa | Oppenheimer | Perform |
| 2022-04-04 | Aggiornamento | Citigroup | Neutral → Buy |
| 2022-03-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2022-03-22 | Downgrade | Citigroup | Buy → Neutral |
| 2022-03-22 | Downgrade | Guggenheim | Buy → Neutral |
| 2022-03-22 | Downgrade | Oppenheimer | Outperform → Perform |
| 2021-07-06 | Aggiornamento | Citigroup | Neutral → Buy |
| 2021-01-25 | Downgrade | Citigroup | Buy → Neutral |
| 2020-08-13 | Iniziato | Robert W. Baird | Outperform |
| 2020-08-06 | Aggiornamento | Citigroup | Neutral → Buy |
| 2020-08-03 | Iniziato | H.C. Wainwright | Buy |
| 2020-05-19 | Iniziato | Citigroup | Neutral |
| 2020-05-19 | Iniziato | Guggenheim | Buy |
| 2020-05-19 | Iniziato | JP Morgan | Overweight |
| 2020-05-19 | Iniziato | Jefferies | Buy |
Mostra tutto
Oric Pharmaceuticals Inc Borsa (ORIC) Ultime notizie
Integral Health Asset Management LLC Cuts Stock Position in Oric Pharmaceuticals, Inc. $ORIC - MarketBeat
Oric Pharmaceuticals (ORIC) Sees Opportunity Amid Market Dynamics - GuruFocus
Oric Pharmaceuticals' (ORIC) Buy Rating Reaffirmed at HC Wainwright - MarketBeat
ORIC Pharmaceuticals Reiterates 'Buy' Rating with $25 Target by HC Wainwright | ORIC Stock News - GuruFocus
Why ORIC Pharmaceuticals (ORIC) Is Down 15.1% After Ipsen Pulls Tazverik Over Safety Concerns - Yahoo Finance
ORIC Pharmaceuticals (ORIC) Is Down 15.1% After Peer Drug Withdrawal Triggers Safety ScrutinyWhat's Changed - simplywall.st
Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
A Look At ORIC Pharmaceuticals (ORIC) Valuation After Recent Share Price Volatility - Yahoo Finance
JPMorgan reiterates Overweight on ORIC Pharmaceuticals stock By Investing.com - Investing.com Canada
Oric Pharmaceuticals celebrates Employee Appreciation Day with recognition initiatives - Traders Union
Oric Pharmaceuticals (NASDAQ:ORIC) Stock Price Up 8.8%Here's Why - MarketBeat
Gilead Gets a Buy, Amgen a Hold and ORIC a Vote of Confidence: Wall Street’s Latest Biopharma Calls Explained - AOL.com
Gilead Gets a Buy, Amgen a Hold and ORIC a Vote of Confidence: Wall Street's Latest Biopharma Calls Explained - 24/7 Wall St.
Constructive Buy Thesis on ORIC Driven by Differentiated PRC2 Biology and Manageable Safety Profile for Rinzimetostat - TipRanks
March 2026 Cantor Fitzgerald Maintains Overweight on ORIC (ORIC) - Meyka
ORIC Stock Recovers Amid Potential for Long-Term Success Despite Temporary Setback - GuruFocus
Oric Pharmaceuticals (NASDAQ:ORIC) Shares Gap DownWhat's Next? - MarketBeat
Technical Reactions to ORIC Trends in Macro Strategies - Stock Traders Daily
Oric Pharmaceuticals stock tumbles on Tazverik withdrawal By Investing.com - Investing.com Australia
Oric Pharmaceuticals stock tumbles on Tazverik withdrawal - Investing.com UK
Jones Trading reiterates Buy on ORIC Pharmaceuticals stock By Investing.com - Investing.com Canada
ORIC Pharmaceuticals Shares Drop Following Ipsen's Drug Withdrawal - GuruFocus
After Golden Cross, Oric Pharmaceuticals, Inc. (ORIC)'s Technical Outlook is Bright - Finviz
ORIC Pharmaceuticals: Differentiated PRC2 Inhibitor Rinzimetostat Mitigates Sector Safety Overhang and Supports Buy Rating - TipRanks
After the Golden Cross, the technical perspective for Oric Pharmaceuticals, Inc. (ORIC) appears promising - Bitget
Is ORIC Pharmaceuticals Inc. stock positioned for digital transformation2026 Drop Watch & Reliable Breakout Stock Forecasts - Naître et grandir
Trend Report: What is ORIC Pharmaceuticals Inc.’s market positionGap Down & Entry Point Confirmation Signals - baoquankhu1.vn
Oric Pharmaceuticals reports inducement grants under Nasdaq listing rule 5635(c)(4) - marketscreener.com
Oric Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - TradingView
ORIC Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - 富途牛牛
A Look At ORIC Pharmaceuticals (ORIC) Valuation After Earnings Update And New Shelf Registration - simplywall.st
JPMorgan Chase & Co. Has $14.74 Million Position in Oric Pharmaceuticals, Inc. $ORIC - MarketBeat
Is ORIC’s ESOP Shelf And Narrower Quarterly Loss Altering The Investment Case For ORIC (ORIC)? - simplywall.st
History Review: What is ORIC Pharmaceuticals Incs market position2025 Volatility Report & AI Enhanced Trading Alerts - baoquankhu1.vn
ORIC Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Oric Pharmaceuticals, Inc. $ORIC Stake Raised by Royce & Associates LP - MarketBeat
Oric Pharmaceuticals Teases Key 2026 Catalysts, Phase 3 Plans for Prostate and Lung Cancer Drugs - MarketBeat
ORIC Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Oric Pharmaceuticals (NASDAQ:ORIC) Stock Rating Upgraded by Wall Street Zen - MarketBeat
Oric Pharmaceuticals, Inc. (ORIC) Stock Analysis: Uncovering a 57% Upside Potential in Biotech - DirectorsTalk Interviews
ORIC Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
ORIC Technical Analysis & Stock Price Forecast - Intellectia AI
Insider Sell: Dominic Piscitelli Sells 52,000 Shares of ORIC Pha - GuruFocus
Dominic Piscitelli Sells 52,000 Shares of Oric Pharmaceuticals (NASDAQ:ORIC) Stock - MarketBeat
Oric Pharmaceuticals Insider Sold Shares Worth $702,686, According to a Recent SEC Filing - marketscreener.com
Oric Pharmaceuticals CFO Dominic Piscitelli Sells 52,000 Shares - TradingView
ORIC (ORIC) CFO exercises options and sells 52,000 shares in 10b5-1 trades - Stock Titan
Wall Street Analysts Believe Oric Pharmaceuticals (ORIC) Could Rally 58.43%: Here's is How to Trade - Finviz
Trading the Move, Not the Narrative: (ORIC) Edition - Stock Traders Daily
Q1 EPS Forecast for Oric Pharmaceuticals Raised by Analyst - MarketBeat
Oppenheimer Sticks to Their Buy Rating for Oric Pharmaceuticals (ORIC) - The Globe and Mail
Oric Pharmaceuticals Inc Azioni (ORIC) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.48%
1.21%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):